UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Optimised and rapid pre-clinical screening in the SOD1(G93A) transgenic mouse model of amyotrophic lateral sclerosis (ALS).

Mead, RJ; Bennett, EJ; Kennerley, AJ; Sharp, P; Sunyach, C; Kasher, P; Berwick, J; ... Shaw, PJ; + view all (2011) Optimised and rapid pre-clinical screening in the SOD1(G93A) transgenic mouse model of amyotrophic lateral sclerosis (ALS). PLoS One , 6 (8) , Article e23244. 10.1371/journal.pone.0023244. Green open access

[thumbnail of journal.pone.0023244.pdf]
Preview
PDF
journal.pone.0023244.pdf

Download (1MB)

Abstract

The human SOD1(G93A) transgenic mouse has been used extensively since its development in 1994 as a model for amyotrophic lateral sclerosis (ALS). In that time, a great many insights into the toxicity of mutant SOD1 have been gained using this and other mutant SOD transgenic mouse models. They all demonstrate a selective toxicity towards motor neurons and in some cases features of the pathology seen in the human disease. These models have two major drawbacks. Firstly the generation of robust preclinical data in these models has been highlighted as an area for concern. Secondly, the amount of time required for a single preclinical experiment in these models (3-4 months) is a hurdle to the development of new therapies. We have developed an inbred C57BL/6 mouse line from the original mixed background (SJLxC57BL/6) SOD1(G93A) transgenic line and show here that the disease course is remarkably consistent and much less prone to background noise, enabling reduced numbers of mice for testing of therapeutics. Secondly we have identified very early readouts showing a large decline in motor function compared to normal mice. This loss of motor function has allowed us to develop an early, sensitive and rapid screening protocol for the initial phases of denervation of muscle fibers, observed in this model. We describe multiple, quantitative readouts of motor function that can be used to interrogate this early mechanism. Such an approach will increase throughput for reduced costs, whilst reducing the severity of the experimental procedures involved.

Type: Article
Title: Optimised and rapid pre-clinical screening in the SOD1(G93A) transgenic mouse model of amyotrophic lateral sclerosis (ALS).
Location: United States
Open access status: An open access version is available from UCL Discovery
DOI: 10.1371/journal.pone.0023244
Publisher version: http://dx.doi.org/10.1371/journal.pone.0023244
Language: English
Additional information: © 2011 Mead et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. PMCID: PMC3158065
Keywords: Amino Acid Substitution, Amyotrophic Lateral Sclerosis, Animals, Disease Models, Animal, Disease Progression, Gait, Hindlimb, Humans, Magnetic Resonance Imaging, Mass Screening, Mice, Mice, Inbred C57BL, Mice, Transgenic, Muscles, Muscular Atrophy, Neuromuscular Junction, Organ Size, Reproducibility of Results, Superoxide Dismutase, Time Factors
UCL classification: UCL
UCL > Provost and Vice Provost Offices > UCL BEAMS
UCL > Provost and Vice Provost Offices > UCL BEAMS > Faculty of Maths and Physical Sciences
UCL > Provost and Vice Provost Offices > UCL BEAMS > Faculty of Maths and Physical Sciences > Dept of Chemistry
URI: https://discovery.ucl.ac.uk/id/eprint/1387297
Downloads since deposit
108Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item